• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

    1/13/26 5:00:00 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email

    New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company" or "China SXT"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS").

    Under the terms of the securities purchase agreement, the Company has agreed to sell to a single investor an aggregate of 66,666,666 of the Company's Class A ordinary shares, no par value per share, (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.15 per share in the Offering. The purchase price for the pre-funded warrants is identical to the purchase price for the Shares, less the exercise price of $0.001 per share.

    The aggregate gross proceeds to the Company were approximately $10 million.

    Univest Securities, LLC acted as the sole placement agent.

    The registered direct offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) previously filed by the Company with the U.S. Securities and Exchange Commission ("SEC") and became effective on December 1, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering were filed with the SEC and are available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Univest Securities, LLC at [email protected], or by calling +1 (212) 343-8888.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus, can be obtained at the SEC's website at www.sec.gov.

    About Univest Securities, LLC

    Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally, including brokerage and execution services, sales and trading, market making, investment banking and advisory, and wealth management. It strives to provide clients with value-added service and focuses on building long-term relationships with its clients. As a prominent name on Wall Street, Univest has successfully raised over $1.7 billion in capital for issuers across the globe since 2019 and has completed approximately 100 transactions spanning a wide array of investment banking services in various industries, including technology, life sciences, industrial, consumer goods, etc. For more information, please visit: www.univest.us.

    About China SXT Pharmaceuticals, Inc.

    Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

    Forward-Looking Statements

    This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. Univest Securities LLC and the Company undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

    For more information, please contact:

    Univest Securities, LLC

    Edric Guo

    Chief Executive Officer

    75 Rockefeller Plaza, Suite 18C

    New York, NY 10019

    Phone: (212) 343-8888

    Email: [email protected]



    Primary Logo

    Get the next $SXTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTC
    SEC Filings

    View All

    SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

    6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    1/13/26 4:05:03 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

    424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    1/12/26 10:50:39 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

    6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    12/31/25 4:01:02 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China SXT Pharmaceuticals, Inc. Announces Share Consolidation

    TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the o

    1/30/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

    TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced as part of its Artificial Intelligence (AI) Insight Initiative to explore the application of Artificial Intelligence (AI) and related digital technologies across the Traditional Chinese Medicine (TCM) raw-material supply chain. This initiative is pa

    1/15/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

    New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company" or "China SXT"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS")

    1/13/26 5:00:00 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTC
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    $SXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    10/25/24 12:19:29 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    8/15/24 9:45:36 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    5/31/24 10:36:52 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care